ERC Consolidator Grant · 2016
Protection of cardiometabolic inflammation by modulation of myeloid glutamine homeostasis
The metabolic syndrome (MetS) represents one of the major public health challenges worldwide. It reflects a combination of medical disorders that, when occurring together, increase the risk of developing diabetes and cardiovascular disease. The prevalence in the USA is estimated at 30% of the population and the European community follows this trajectory. It is now recognized that the state of chronic low-grade inflammation may favor the onset and progression of the MetS. While the notion of metabolic flexibility in hematopoietic cells has recently emerged in several inflammatory diseases, the origin of this immunometabolic alteration in the MetS remains elusive. There is a growing…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at National Institute of Health and Medical Research (INSERM)